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Background: Lectin immunosorbant assays (LISAs) have been widely used for analyzing protein glycosylation.
However, the analysis of serum samples by LISAs could suffer from high sample-dependent background noise. The aim
of this study is to develop a differential lectin immunosorbant assay (dLISA) with reduced background interferences.
Methods: For the analysis of protein glycosylation, dLISA establishes a dose–response curve for every serum sample.
The sample is split into five aliquots. Four aliquots undergo differential removal of the glycoprotein of interest by
immunoprecipitation. Then, all five aliquots are subject to two measurements: protein by immunoassay and protein
glycans by LISA. A dose–response curve is established by plotting glycans signals on the y-axis and protein levels on
the x-axis for all the aliquots. Slope of the curve, calculated by linear progression analysis and expressed as fluorescence
per concentration of protein, is used for the measurement of protein glycosylation in the serum sample.
Results/conclusions: To demonstrate the feasibility of the dLISA approach, we used recombinant, fucosylated tissue
inhibitor of metallopeptidase 1 (TIMP-1) as the target glycoprotein. Magnetic beads based TIMP1 immunoassay and
TIMP-1 UEA LISA were developed for the measurement of TIMP1 protein and terminal α1, 2 fucosylated glycans on
TIMP1, respectively. Serum samples supplemented with differentially fucosylated recombinant TIMP-1 were used to
demonstrate that the slopes measured the TIMP-1 fucosylation, and were less prone to background interference.
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Aberrant glycosylation of proteins has been implicated
in many human diseases [1-3]. To aid in the diagnosis
and prognosis, as well as in the understanding of these
diseases at the molecular levels, there have been many
research initiatives focusing on the development of ana-
lytical tools for effective analyses of subtle, yet biological
significant, glycosylation changes [4-9]. One of the most
informative and sensitive detection techniques for the
analysis of glycans and glycoproteins is mass spectrom-
etry (MS). Analytical tools combining MS with separ-
ation and enrichment techniques such as hydrophilic
interaction chromatography (HILIC) and immunoaffinity
enrichment are expected to provide a wealth of informa-
tion on glycosylation changes that would allow a better* Correspondence: dannili@umn.edu
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reproduction in any medium, provided the orunderstanding of the biological attributes of glycopro-
teins [10-13].
Complementary to the MS based techniques are affinity-
based techniques for the analysis of glycosylation changes,
such as lectin immunosorbant assays (LISAs) [4,6,14-16].
LISAs are similar to enzyme-linked immunosorbant assays
(ELISA) except that lectins are used as probes for detecting
glycan structures (Figure 1A). The potential advantages
of LISAs are several. First, LISAs are easy to set up. They
can share the same instrument as the existing proteins
immunoassays. Second, LISAs, when developed together
with protein immunoassays, could generate integrated
protein-glycan information [17]. Third, LISAs provide
easy-to-interpret information that does not require so-
phisticated bioinformatics tools and supporting data-
base. Lastly, due to lectins’ broad specificities, LISAs
could provide additional information on all the glycans
that the lectins bind to and resulting in better sensitivity
for the detection of glycosylation changes of proteins.
LISAs have been used in the discovery and validation
of glycosylation of proteins as biomarkers [4,6,14-16].his is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Schematic representation of LISAs. In LISAs, antibody captures the protein of interest and lectin detects the glycan structures on the
protein (Figure 1A). Lectins would bind to antibodies (Figure 1B) and non-specific bound proteins (e.g., to the antibody and/or to solid surface
that the antibody was adhered to) (Figure 1C-D).
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widely exploited. In LISAs, lectins could bind to antibodies
since antibodies are glycoproteins, resulting in high back-
grounds that could reduce sensitivity (Figure 1B). Several
ways of blocking the lectin-antibody binding have been
used in LISAs, such as (i) enzymatic release of the glycans
off the antibody and (ii) oxidation of the glycans followed
by derivatization with di-peptides. Although these treat-
ments were able to reduce the background signals, reduc-
tion varied by lectin [4,16,18]. For some lectins (e.g.,
Pisum savitum Lectin and Lens Culinaris Agglutinin),
background signals after blocking were still too high [16].
Lectins could also bind to non-specific bound proteins
(e.g., to the antibody and/or to solid surface that the anti-
body was adhered to) (Figure 1C-D). This could be prob-
lematic, especially when serum specimens are used,
because the majority of serum proteins are glycosylated.
The non-specific bound proteins could be reduced by thecareful selection of blocking conditions. However, they
could not be completely eliminated. Furthermore, the
non-specific binding may vary from sample to sample.
The sample-dependent background introduces significant
variations in the signal generated by LISAs, making the
comparison of glycosylation changes of proteins unreli-
able. In this study, we developed a dLISA approach for the
analysis of protein glycosylation in serum that was less
prone to background interference.
Materials and methods
Reagents
TIMP-1 capture antibody, TIMP-1 biotinylated detection
antibodies, and recombinant TIMP-1 protein were pur-
chased from the R&D Systems (Minneapolis, MN). Bio-
Plex Pro™ magnetic COOH beads, Amine Coupling Kits,
and Cytokine Assay Kits were purchased from Bio-Rad
Laboratories (Hercules, CA). Biotinylated Ulex europaeus
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(Burlingame, CA). Dynabeads Antibody Coupling Kit was
purchased from Invitrogen (Carlsbad, CA).
Clinical specimens
Serum samples from cancer and non-cancer patients
(breast cancer, colon cancer, hepatocellular carcinoma,
ovarian cancer, lung cancer, and prostate cancer) were
obtained from the Serum Bank at the Center for Biomarker
Discovery and Translation, Johns Hopkins University
(Baltimore, MD) with the approval from the institu-
tional review board.
TIMP-1 immunoassay
TIMP-1 immunoassay was developed using the BioRad
Cytokine Assay Kit (Hercules, CA). TIMP-1 capture anti-
body was coupled to Bio-Plex Pro™ magnetic COOH beads
using the BioRad Amine Coupling Kit. The coupling was
then validated using biotinylated goat anti-mouse IgG anti-
bodies (Sigma-Aldrich, St. Louis, MO) to ensure binding of
the capture antibody to the beads. After the validation, the
beads were counted, and stored in the storage buffer at 4°C.
For the TIMP-1 immunoassay, 2500 of the beads (per well
for a 96-well plate) were incubated with 50 μL of a serum
sample diluted in the Sample Diluent (provided in the
BioRad Cytokine Assay Kit) at room temperature for 60 mi-
nutes. After the incubation, the beads were washed and
incubated with 25 μL of 2 μg/mL biotinylated TIMP-1 de-
tection antibody diluted in the Detection Antibody Diluent
(provided in the Cyotkine Assay Kit) at room temperature
for 30 minutes. Then the beads were washed again and in-
cubated with 50 μL of 2 μg/mL streptavidin-phycoerytherin
diluted in the Assay Buffer (provided in the Cyotkine Assay
Kit) at room temperature for 10 minutes before analysis
using the Bioplex 200 System (BioRad, Hercules, CA).
Bioplex 200 uses 635 nm solid-state Laser to excite the
fluorescent dyes inside the magnetic COOH beads to pro-
vide bead classification and assay identification information,
and uses 532 nm Nd-Yag Laser to excite the phycoerytherin
dye to generate a reporter signal. Recombinant TIMP-1
was used as standard. Concentrations of 0, 0.02, 0.1, 0.39,
1.56, 6.25, and 25 ng/mL of recombinant TIMP-1 were pre-
pared in the Standard Diluent (provided in the Cytokine
Assay Kit) as calibrators for establishment of a calibration
curve for TIMP-1 protein quantification.
TIMP-1 UEA LISA
TIMP1 UEA LISA was established the same way as the
TIMP1 immunoassay except that 20 μg/mL of biotinylated
UEA was used for detection.
Immunoprecipitation of endogenous TIMP-1 in serum
Immunoprecipitation of endogenous TIMP-1 in serum
was achieved using Dynabeads coupled with TIMP1capture antibody. The coupling of the TIMP-1 capture
antibody to the Dynabeads was performed using the
Dynabeads Antibody Coupling Kit. For the immunopre-
cipitation, every 10 μL of serum was mixed with 5 μL of
the coupled Dynabeads. The amount of beads (5 μL)
was empirically determined to be the sufficient for the
complete removal of endogenous TIMP-1 from serum
samples. The mixture was then incubated on a rotator
overnight at 4°C. For partial removal of the endogenous
TIMP-1, fewer beads (e.g., 3uL) would be used.
Production of the differential fucosylated recombinant
TIMP-1
Four microliter of the recombinant TIMP-1 (10 μg/mL
prepared in PBS + 1% BSA buffer) was mixed with 4 μL
of α1, 2 fucosidase (Catalog# P0724, New England
Biolabs, Ipswich, MA). The mixture (8 μL) was then di-
luted 5 times in the 32 μL of the Reaction buffer
(50 mM Sodium Citrate, 100 mM Sodium Chloride,
pH 6.0) for incubation of 0, 15, 30, or 45 minutes with
shaking at 37°C. After the incubation, each mixture was
spiked into a serum aliquot. Presence of large quantities
of glycoproteins in serum would stop the enzymatic di-
gestion of the TIMP-1 by α1, 2 fucosidase. The serum
aliquot did not contain endogenous TIMP-1, which was
immuno-depleted. The immuno-depletion was con-
firmed using the TIMP-1 immunoassay.
Data analysis
Calibration curve for the TIMP-1 immunoassay was
established using the 5-parameter nonlinear regression
model in Bio-Plex Manager™ 6.0. Protein concentrations
were calculated using the calibration curve and reported
by Bio-Plex Manager™ 6.0. For linear regression and stat-
istic analysis of the dose–response curves, we used
Graphpad Prism 5.04. Limit of detection of the TIMP-1
immunoassay, determined using 3 times of standard de-
viation of the zero calibrator over six measurements,
was 0.01 ng/mL. Reproducibility of the TIMP-1 immu-
noassays, determined using the coefficient variance of
the calibrators at concentrations of 0.02, 0.1, 0.39, 1.56,
6.25, and 25 ng/mL, was less than 20%.
Results
Overview of the dLISA approach
Using TIMP-1 fucosylation as an example, the dLISA
approach of measuring glycosylation of serum proteins
is described in Figure 2. A serum sample (S) is splitted
into five aliquots (A1 to A5) with equal volume. Mag-
netic beads coupled with TIMP-1 antibodies are used for
the removal of endogenous TIMP-1 in these aliquots:
A1 is left untreated, whereas A2 to A5 are treated with
increasing amounts of magnetic beads for the differential
removal; the amount of beads used for A5 is sufficient
Figure 2 Schematic representation of the dLISA approach. (A) A serum sample is split into five aliquots (A1 to A5). (B) Four of these aliquots
are treated with increasing amounts of magnetic beads coupled with TIMP-1 antibody to gradually reduce the amount of endogenous TIMP-1
present. For aliquot A5, there should be sufficient beads used for complete removal of the endogenous TIMP-1. (C) After the magnetic beads
treatment, the beads were separated using a magnetic separator and the supernatant from each aliquot is transferred. (D) Both TIMP-1 UEA LISA
assay and TIMP-1 immunoassay are performed on each aliquot. (E) A dose–response curve is constructed using the measured TIMP-1
concentration (ng/mL) in each aliquot by the TIMP-1 immunoassay along with the corresponding fluorescence readout by the TIMP-1 UEA
LISA assay.
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After the treatments, all the five aliquots are subject to
the measurement by two methods: TIMP-1 immuno-
assay and TIMP-1 UEA LISA assay. The immunoassay
is used to determine TIMP-1 protein levels in these ali-
quots, which should have decreasing levels of TIMP1
from A1 to A5; the TIMP-1 UEA LISA assay is used for
the detection of UEA-associated, α1, 2 fucosylated gly-
cans. As explained previously, LISA assays are prone to
interferences. To tease out the portions of the signals
that are specific for TIMP-1, the TIMP-1 UEA LISA
signals of A1 to A5 are plotted on the y-axis against
their respective TIMP-1 protein levels on the x-axis to
establish a dose–response curve. Linear progression ana-
lysis determines the slope of the dose–response curve,
which is expressed as fluorescence (A.U.) per TIMP-1concentration (ng/mL). The slope reflects the changes in
the TIMP-1 UEA LISA signal as a result of changes in
TIMP-1 concentration (ng/mL).
Although LISA assay appears to be similar to dLISA
assay, they are different in several ways: (1) LISA assay is
performed as a single measurement, whereas dLISA
assay establishes a dose–response curve based on meas-
urement of five aliquots; (2) LISA assay measures both
protein abundance as well as protein glycosylation, both
of which are combined together and reported as a single
read out; on the other hand, the dLISA approach
includes protein immunoassay, separating protein abun-
dance from protein glycosylation, and therefore, specific-
ally measures protein glycosylation; (3) Because it
differential removed the target protein using immuno-
precipitation, the dLISA approach is more specific for
Li et al. Clinical Proteomics 2013, 10:12 Page 5 of 9
http://www.clinicalproteomicsjournal.com/content/10/1/12the target protein; (4) The dLISA approach also includes
measurement of the background signal through the ali-
quot A5. This helps to identify serum samples with po-
tential high background signal that interferes with LISA
assay, and thus it demonstrates the advantages of the
dLISA approach with reduced interferences.
Correlation of the slope with serum TIMP-1 fucosylation
We demonstrated that the slopes of the dose response
curves correlated TIMP-1 fucosylation using recombin-
ant TIMP-1. The NS0 cell line derived recombinant
TIMP-1 (R&D Systems, Minneapolis, MN) contains ter-
minal α1, 2 fucosylated glycans associated with UEA
[19]. First, we prepared 4 serum samples with differen-
tially fucosylated TIMP-1 by treating the recombinant
TIMP-1 with α1, 2-fucosidase at various time lengths (0,







Figure 3 Slopes of the dose response curves established using the dL
response curves of serum samples spiked with differentially fucosylated rec
at different length of time (0, 15, 30, and 45 minutes) before they were spi
pool of sera with endogenous TIMP-1 immuno-depleted (confirmed by the
serum samples underwent the dLISA approach. (B) A graph presentation o
length of fucosidase treatment (minutes).fucose, to which UEA has specificity towards. The longer
the treatment was, the more α1, 2 fucose was cut off
from TIMP-1, and the less fucosylated the TIMP-1 be-
came. Therefore, the four treatment conditions (0, 15,
30, and 45 mins) created recombinant TIMP-1 proteins
with 4 differential levels of fucosylation. These proteins
were then spiked into four serum aliquots (S1 to S4) that
did not contain endogenous TIMP-1 (Endogenous
TIMP-1 in these aliquots was immuno-depleted and con-
firmed using the TIMP-1 immunoassay). Second, each of
these four samples (S1 to S4) underwent the dLISA ap-
proach. Curves and slopes of these four samples are illus-
trated in Figures 3A and 3B, respectively. The level of
fucosylation decreased in these samples from S1 to S4, so
were the linear regression slopes, decreasing from
20 ±2, 12± 2, 6 ± 1, to 5± 1 (fluorescence/ (ng/mL








ISA approach correlated with TIMP-1 fucosylation. (A) Dose–
ombinant TIMP-1. Recombinant TIMP-1 was treated by α1, 2 fucosidase
ked into with four serum aliquots. These aliquots came from the same
TIMP-1 immunoassay). After the recombinant protein spiked in, these
f linear regression slopes of the dose–response curves versus the
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and the slopes was −0.96 (95% confidence interval of
−0.99 to −0.05, one-tailed p value of 0.02), indicating
that the slopes correlated with the levels of TIMP-1
fucosylation.
Application of the dLISA approach to serum samples
We applied the dLISA approach to serum samples in
oder to demonstrate its advantages over LISA using 4
specimens (C1 to C4) with the same fucosylated TIMP-1
in different serum matrices. Figure 4A and 4B shows the
dose–response curves and slopes of the dLISA approach,
respectively. Signals of the LISA assay (or the TIMP-1
UEA LISA) for these specimens were shown by the y-
axis of Figure 4A. The dLISA approach indicated that
the slope of C2 was not statistically significant from that
of C1, C3, or C4 (32 ± 5 for C2 vs. 22 ± 3 for C1, or 26
± 3 for C3, or 25 ± 4 for C4), consistent with the fact
that these specimens contain the same recombinant
TIMP-1. However, the y-axis (Figure 4A) showed theA
B
Figure 4 Dose-response curves and slopes of the dLISA approach wh
in different serum matrices. (A) Dose–response curves of four samples w
of these specimens, we identified four individual serum samples. Each one
TIMP-1 (confirmed by the TIMP-1 immunoassay). Recombinant TIMP-1 was
underwent the dLISA approach. (B) A bar graph with linear regression slophigher LISA signals of C2 than those of C1, C3, or C4 at
any given TIMP-1 protein concentrations (x-axis in
Figure 4A), indicating that C2 contained TIMP-1 with
higher level of fucosylation than that of C1, C3, or C4,
inconsistent with the fact that these specimens contain
the same recombinant TIMP-1. This was due to the
higher background signal of C2 (265) than those of C1,
C3, or C4 (94, 103, or 75, respectively), as indicated
when TIMP-1 was completely removed in these speci-
mens (when TIMP-1 protein concentration was 0 ng/
mL). Therefore, we demonstrated that the dLISA ap-
proach was less prone to the background interference
than LISA.
We also applied the dLISA approach to serum samples
from normal and cancer conditions. Figure 5 showed the
dose–response curves of the four normal serum samples
N1, N2, N3, and N4. Serum N3 and N4 had the slopes
of −0.3 ± 0.1, and 0.65 ± 0.04, respectively. Both slopes
were close to zero, indicating that TIMP-1 in both sera








en applied to serum specimens with the same fucosylated TIMP-1
ith the same fucosylated TIMP1 in different matrices. For preparation
of them was then treated for complete removal of endogenous
added into each of the serum matrices. Then these serum samples





Figure 5 Dose–response curves of serum samples from 4 healthy subjects. Healthy serum samples 1, 2, 3, and 4, represented by the
orange, green, red, and blue-colored lines, respectively. Each serum sample underwent the dLISA approach.
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tion in TIMP-1 protein increased the fluorescence of
UEA detection in both serum N1 and N2. This indicated
the existence of interferences with the LISA UEA assay
in serum N1 and N2. Nevertheless, the slopes of N1 and
N2, -0.1 ± 1.5, and −4 ± 1, respectively, were consistent
with N3 and N4, that serum TIMP-1 had little UEA
fucosylation. UEA fucosylation pattern of TIMP-1 were
also analyzed in six different cancers (breast cancer,
colon cancer, hepatocellular carcinoma, ovarian cancer,
lung cancer, and prostate cancer). Linear regression
slopes of their dose–response curves (shown in Table 1
and Additional file 1: Figure S1) were close to zero for
breast cancer, colon cancer, hepatocellular carcinoma,
and lung cancer, indicating that serum TIMP-1 had little
or no UEA fucosylation in these cancer conditions.
Discussion
TIMP-1 belongs to a family of tissue inhibitors of matrix
metalloproteinases (MMPs) whose inhibitory activities
play important roles in cellular homeostasis, tissue re-
modeling, and oncogenesis [20]. Expression of TIMP-1
was increased in cancer tissue in prostate [21]. TIMP-1Table 1 Linear-regression slopes of the dose–response curves
cancer, colon cancer, HCC, ovarian cancer, lung cancer, and p
Slope
Specimen # Normal Breast cancer Colon cancer
1 -0.1 ± 1.5 -0.9 ± 0.1 0.09 ± 0.13
2 -4 ± 1 -2 ± 0 0.07 ± 0.22
3 0.7 ± 0.0 -1 ± 0 -0.5 ± 0.2 -
4 -0.3 ± 0.0 -0.8 ± 0.3 0.8 ± 0.2 0was reported to have prognostic and predictive value in
breast cancer [22,23], and serum TIMP-1 was a predictor
of survival outcomes in colorectal cancer [24]. In addition,
TIMP-1 has been implicated in MMP-independent ac-
tions, such as synaptic plasticity of the central nervous
system [25].
Aberrant glycosylation of TIMP-1 was implicated in cancer
progression. Increased β1, 6 branching of N-glycans of
TIMP-1, induced by GnT-V N-acetylglucosaminyltransferase,
was closely correlated with invasive/metastatic potential
of colon cancer cell WiDr [26]. Detection of TIMP-1
UEA α1, 2 fucosylation in prostate tissues was found to
be superior to TIMP-1 protein in distinguishing aggres-
sive and non-aggressive prostate cancer [17]. Whether
detection of TIMP-1 UEA fucosylation in serum could
help identify aggressive prostate cancer remained to be
determined. We measured TIMP-1 UEA fucosylation
in sera of prostate cancer and found little UEA
fucosyaltion. The seemingly contradictory findings be-
tween prostate tissues and sera could be due to the
source differences of TIMP-1. Presence of TIMP-1 in
serum may be a combination of physiology (e.g., for car-
rying out their functions in circulation), tissues leakagesof four individual serum samples of normal, breast
rostate cancer
s
HCC Ovarian cancer Lung cancer Prostate cancer
-1 ± 0 2 ± 0 -0.4 ± 0.3 2 ± 1
-1 ± 0 0.5 ± 0.5 -0.6 ± 0.5 1 ± 0
0.3 ± 0.0 2 ± 0 2 ± 0 0.51 ± 0.04
.5 ± 0.1 2 ± 1 -0.2 ± 0.2 0.1 ± 0.2
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rant secretions (e.g., released from tumors and other
disease tissues, presumably not as a result of a func-
tional requirement) [27]. Given the potential sources of
TIMP-1 in serum, if TIMP-1 from other sources were
not fucosylated, the contribution of prostate tissue
TIMP-1 would be too small to be detected. The same
pattern was also observed in non-cancer sera and sera
of other cancers such as breast, colon, lung, and ovar-
ian, indicating that (1) TIMP-1 from other tissues may
not be fucosylated, and (2) there was no difference in
serum TIMP-1 fucosylation between non-cancer and
cancers. This latter finding was consistent with
Thaysen-Anderson et al., which showed no significant
difference of TIMP-1 glycoprofiles between normal and
colon cancer [9].
Ahn et al. showed that Leukocyte phytohemagglutinin
(L-PHA) captured glycoforms of TIMP-1 in a pooled
colon cancer serum was 5 times higher in abundance
than that in a pooled non-cancer serum by mass spec-
trometric analysis [28]. We did not try TIMP-1 L-PHA
LISA in serum because the recombinant TIMP-1 did
not have L-PHA bound glycans [19] and therefore could
not be used as the standard protein for the feasibility
study. This points out a bigger issue in the field of
glycobiology. In the future, development of protein en-
gineering technology that allows additions of glycans of
interest to proteins and produces highly purified protein
glycoforms [29] would help solve this problem.Conclusions
Using recombinant TIMP-1 as the model, we determined
a dLISA approach for the analysis of serum protein glyco-
sylation that was less prone to potential interference of
serum matrices. Applying the approach of analysis TIMP-
1 fucosylation in serum samples, we found that serum
TIMP-1 had little or no α1, 2 fucosylation in normal and
many cancer conditions.Additional file
Additional file 1: Figure S1. Dose-response curves of serum samples
of breast cancer (A), colon cancer (B), HCC (C), ovarian cancer (D), lung
cancer (E), and prostate cancer (F). For each condition, there are four
samples 1, 2, 3, and 4, represented by the orange, green, red, and
blue-colored lines, respectively.Competing interests
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